HORMONE RECEPTOR POSITIVE BREAST CANCER AND THERAPY RESISTANCE
Professor Elgene Lim
Laboratory Head Connie Johnson Breast Cancer Research Lab,
Garvan Institute of Medical Research, Sydney &
Oncologist, The Kinghorn Cancer Centre, St Vincent’s Hospital, Sydney
RESEARCHER PROFILE (Filmed in Brisbane, Queensland, Australia | October 2024)
Prof Elgene Lim is a medical oncologist at St Vincent’s Hospital and Head of the Connie Johnson Breast Cancer Research Lab at the Garvan Institute. Following his PhD at the Walter & Eliza Hall Institute where he identified the aberrant cells in carriers of the BRCA1 mutant gene, a hereditary breast cancer syndrome as the culprit cells giving rise to breast cancer, he furthered his research and clinical training at the Dana-Farber Cancer Institute and Harvard Medical School. He was awarded the National Breast Cancer Foundation Practitioner Fellowship in 2014 and returned from Boston to Australia. In 2017, he was awarded the inaugural National Breast Cancer Foundation Endowed Chair, and subsequently appointed the Principal Cancer Theme Lead at UNSW.
His research focus is in the area of breast cancer, specifically bringing laboratory findings into clinical studies and evaluation of novel therapies in clinical trials. His team, in partnership with patients, have established a large panel of patient derived breast cancer avatars in mice, which allow for the study of breast cancer biology and the evaluation of novel therapies.
You Might also like
-
World-first clinical trial improves patient outcomes for kidney transplants (2023)
A world-first clinical trial conducted at the Royal Adelaide Hospital (RAH) and at hospitals across Australia and New Zealand has identified the best fluid treatment to reduce the risk of patients requiring dialysis after a kidney transplant.
Around one in three people who receive a kidney transplant suffer delayed graft function, which means the transplant doesn’t work immediately and they require dialysis.
The lead-author of the study, was Royal Adelaide Hospital Nephrologist and University of Adelaide researcher, Dr Michael Collins.
-
Food and fasting periods as medicine to prevent disease
Professor Leonie Heilbronn is based at the South Australian Health and Medical Research Institute (SAHMRI), where she leads the Obesity and Metabolism laboratory. Her research is at the interface between basic and clinical science. She is internationally recognised for her work in nutritional modulation in humans and has made major contributions to our current understanding of mechanisms underlying conditions such as insulin resistance, particularly inflammation and lipid metabolism. She has also contributed significantly to current concepts of caloric restriction (CR), intermittent fasting (IF) and time restricted eating (TRE) in humans. She has published more than 110 peer reviewed papers in scientific journals and is an Associate Editor of Obesity, and Obesity Research and Clinical Practice.
-
Biopsychosocial approaches to obsessive-compulsive, body image and eating disorders
Dr Nicola Acevedo is a Neuroscientist and Research Fellow with extensive expertise in developing novel therapeutics for neurological and psychiatric disorders, contributing to more than ten clinical trials. She specialises in brain stimulation and psychedelic treatments for obsessive-compulsive disorder (OCD) and related conditions, with a strong commitment to advancing personalised, evidence-based neurobiological therapies for severe psychiatric illness. Her approach integrates biopsychosocial and person-centred principles to improve treatment access and mental health outcomes.